Capricor Therapeutics, Inc.
NASDAQCapricor Therapeutics closes the July 4 week at $23.21 — down 24% on the month, 24% on the week — with the short position still near multi-month highs and the August 6 earnings date drawing closer. The structural short story hasn't changed, but there are early signs of partial relief. Bears hold 28.4% of the free float — roughly 13 million shares — up 3.8% on the week and 19% over…
CAPR short interest surges to 31.8% of float, up 20.3% in one week as bears rebuild aggressively despite stock falling 22% over same period.
A new long-form analysis for CAPR this week — anomalies vs the company's own history, peer comparisons, news context, and the full data picture. Premium subscribers only.
Read on ORTEX →Sign up for premiumCapricor Therapeutics closes the July 4 week at $23.21 — down 24% on the month, 24% on the week — with the short position still near multi-month highs and the August 6 earnings date drawing closer. The structural short…
Snapshot as of 5 Jul 2026
Capricor Therapeutics enters the July 4 week having shed another 24% on the month to $23.21, with a fresh cluster of insider selling landing precisely as the bear thesis continues to play out. The insider activity is…
Capricor Therapeutics fell 13% on Friday to $26.44, erasing the twin weekly gains that had animated two consecutive "bears losing ground" narratives — and the short position that rebuilt so aggressively last week shows…
Capricor Therapeutics just delivered a second consecutive weekly gain, but the short position that was showing its first real cracks last week has snapped back with unexpected force. The most striking development since…
Capricor Therapeutics has delivered its sharpest weekly gain in months — up 13.3% to $28.38 — and for the first time since the bear campaign peaked, the short position is visibly retreating rather than merely…
Capricor Therapeutics heads into the weekend with a stock that bounced 3% on Friday but remains 18% below where it traded a month ago — and a short position that has stabilised rather than retreated. The bear…
Capricor Therapeutics enters the new week with a genuinely interesting tension: the bear campaign that drove short interest to multi-month highs has started to soften, but the stock keeps falling anyway. The short…
Capricor Therapeutics enters the weekend with shorts firmly in control — the stock down 11% on the week, short interest at a multi-month peak, and the borrow market tightening faster than at any point in recent…
Capricor Therapeutics heads into the week with bears back on the offensive — short interest climbing, borrow availability tightening sharply, and the ORTEX short score reaching its highest reading in the observable…
Capricor Therapeutics enters June with its short position entrenched near a multi-month high, a cluster of insider sales fresh in the register, and the stock trading 12% below where it opened May. The short setup has…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CAPR — free to start on ORTEX.
Sign up for free →Open CAPR on ORTEX